Hospital mortality in acute myocardial infarction in the era of reperfusion therapy (the myocardial infarction triage and intervention project)☆
References (18)
- et al.
Prognosis after initial myocardial infarction: the Framingham study
Am J Cordial
(1979) - et al.
Myocardial infarction triage and intervention project-phase 1: patient characteristics and feasibility of prehospital initiation of thrombolytic therapy
J Am Coll Cardiol
(1990) Acute myocardial infarction in the United States, 1970–1983
Am Heart J
(1987)- et al.
In-hospital and 1-year mortality in 1,524 women after myocardial infarction
Circulation
(1991) - et al.
Prognosis and management after a first myocardial infarction
N Engl J Med
(1990) Effectiveness of intravenous thrombolytic treatment in AMI
Lancet
(1986)- et al.
A prospective randomized clinical trial of intracomnary streptokinase vs. coronary angioplasty for AMI
N Engl J Med
(1986) Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in AMI: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial
N Engl J Med
(1989)- et al.
Prognostic significance of ischemic episodes in patients with previous myocardial infarction
Am J Cordial
(1988)
Cited by (65)
Smoking cessation
2004, Clinical Trials in Heart Disease: A Companion to Braunwald's Heart DiseaseMortality of myocardial infarction in the PRIMVAC registry. Prognostic factors
2004, Medicina ClinicaParadoxical effect of smoking in the Spanish population with acute myocardial infarction or unstable angina: Results of the ARIAM register
2004, ChestCitation Excerpt :Therefore, although there is less myocardial preconditioning, they still had lower mortality rates. Most studies2032 that have shown a paradoxical effect of smoking attribute this effect to the covariables mentioned above, particularly with regard to lower age and lower comorbidity. They do not consider that the results of the multivariate analysis indicate the benefits of smoking.
Reduction of myocardial ischemic injury following coronary intervention (The MC-1 to eliminate necrosis and damage trial)
2003, American Journal of CardiologyCitation Excerpt :Considering the relation between increased infarct size, as measured by cardiac enzymes, and adverse cardiovascular events,22–24 these results merit further evaluation of MC-1 to reduce myocardial ischemia, infarction, and/or reperfusion injury in larger, pivotal trials of patients at high risk for developing ischemic complications in the settings of AMI, catheter-based revascularization, and coronary bypass surgery.
- ☆
This study was supported by Grant RO1 HL38454 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland, and by an unrestricted grant from Genentech, Inc., South San Francisco, California.